Skip to main content
Caplight Logo









AUM Biosciences

AUM Biosciences

Private
SingaporeHealthcare & Life Scienceshttps://aumbiosciences.com/

Last Round

Reverse Merger

Jun 8, 2023

Est. Valuation

$469M

Total Funding Raised

$28.5M

Company Overview

AUM Biosciences is a biotechnology company that leverages a proprietary AI-augmented platform to systematically discover and develop targeted cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

precision oncologysmall molecule inhibitorsbiotech startupdrug discoveryclinical-stage biotechasset-light R&Dvirtual biotechtargeted cancer therapyclinical trialsdrug developmentMNK inhibitorTRK inhibitorPI3K inhibitormTOR inhibitorprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AUM Biosciences Comparables

Compare AUM Biosciences with similar companies based on industry and business-model similarity.

AUM Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Boundless Bio
77%
Ono Pharmaceutical Co., Ltd.
77%
Inflection Biosciences
77%

AUM Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Reverse MergerJun 8, 2023
Series AOct 12, 2021
SeedJun 25, 2018

Key People

Founding team and executive leadership

John Patava

Chief Operating Officer

Executive Team

AUM Biosciences Investors

Notable investors and investment history

AUM Biosciences investors
InvestorRounds
SPRIM Global InvestmentsSeries A
SPRIM Global InvestmentsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 8, 2023

    $69M raised with Mountain Crest Acquisition Corp. V.

  • Oct 12, 2021

    $27M round led by Everlife Asia and SPRIM Global Investments.

AUM Biosciences Filings

Explore SEC and related filing metadata, where available.

AUM Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AUM Biosciences's valuation, stock price, and market status.

Is AUM Biosciences a public or private company?

AUM Biosciences is a private company.

What is the current stock price of AUM Biosciences?

AUM Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is AUM Biosciences worth (valuation)?

Valuation information for AUM Biosciences is not publicly available.

Can I buy AUM Biosciences stock?

AUM Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AUM Biosciences's last funding round?

AUM Biosciences's most recent funding round was Series A on October 12, 2021.

Who are the main investors in AUM Biosciences?

Key investors in AUM Biosciences include SPRIM Global Investments.

Will AUM Biosciences IPO soon?

No public IPO plans have been announced for AUM Biosciences.

How can I track AUM Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AUM Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSingapore
Employee Range15
Year Founded2018
Last FundingJun 8, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?